CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.7B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.28: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.94%
Annual Rate
CNY 2.40Paid semi-annual
Payout Ratio
95.7%High
Payback Period
26.7 yr
Last Ex-Dividend
Apr 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.46BCNY1.70B · vs all stocks (USD)
Trailing P/E
26.46xvs Medical Devices peers
Revenue (TTM)
3.66BCNY543.09M · vs all stocks (USD)
Profit Margin
10.57%vs Medical Devices peers
Beta
0.6170xvs all stocks
52-Week Change
15.64%vs all stocks
Forward Annual Dividend Yield
4.94%vs all stocks
Market Capitalization
11.46BCNY1.70B · vs all stocks (USD)
Enterprise Value
8.84BCNY1.31B · vs all stocks (USD)
Trailing P/E
26.46xvs Medical Devices peers
Forward P/E
19.30xvs Medical Devices peers
PEG Ratio
1.70xvs Medical Devices peers
Price to Sales (TTM)
3.20xvs Medical Devices peers
Price to Book (MRQ)
2.16xvs Medical Devices peers
Enterprise to Revenue
2.41xvs Medical Devices peers
Enterprise to EBITDA
18.77xvs Medical Devices peers
Gross Margin
55.15%vs Medical Devices peers
Profit Margin
10.57%vs Medical Devices peers
Operating Margin
13.25%vs Medical Devices peers
Return on Assets (TTM)
3.32%vs Medical Devices peers
Return on Equity (TTM)
7.98%vs Medical Devices peers
Revenue (TTM)
3.66BCNY543.09M · vs all stocks (USD)
Revenue per Share (TTM)
17.94CNYUpdated Aug 19, 2026Quarterly Revenue Growth
37.20%vs Medical Devices peers
Gross Profit (TTM)
1.94BCNY287.98M · vs all stocks (USD)
EBITDA (TTM)
611.23MCNY90.65M · vs all stocks (USD)
Net Income (TTM)
387.23MCNY57.43M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
17.10%vs Medical Devices peers
Operating Cash Flow (TTM)
688.23MCNY102.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
595.17MCNY88.26M · vs all stocks (USD)
Forward Annual Dividend Rate
2.40CNYUpdated Aug 19, 2026Forward Annual Dividend Yield
4.94%vs all stocks
Trailing Annual Dividend Rate
1.80CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
3.71%vs all stocks
Payout Ratio
95.74%vs Medical Devices peers
Minority Interest (Equity)
36.03MCNYFY2025 · Dec 31, 2025Revenue
3.39BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.59BCNYFY2025 · Dec 31, 2025Gross Profit
1.80BCNYFY2025 · Dec 31, 2025Operating Income
395.56MCNY58.66M · vs all stocks (USD)
Pre-tax Income
425.84MCNYFY2025 · Dec 31, 2025Income Tax Expense
55.53MCNYFY2025 · Dec 31, 2025Net Income
370.32MCNYFY2025 · Dec 31, 2025EBIT
441.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
611.23MCNYFY2025 · Dec 31, 2025Research & Development
87.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
757.01MCNYFY2025 · Dec 31, 2025Other Operating Expenses
53.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
26.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
16.07MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
370.32MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
424.46MCNYFY2025 · Dec 31, 2025Free Cash Flow
264.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.29BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
370.32MCNYFY2025 · Dec 31, 2025Other Non-cash Items
43.63MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.77MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-159.89MCNYFY2025 · Dec 31, 2025Net Acquisitions
-126.27MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.05BCNYFY2025 · Dec 31, 2025Sale of Investments
2.26BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-68.96MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.16BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.25BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-371.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.72MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-468.75MCNYFY2025 · Dec 31, 2025Shares Outstanding
208.90MSharesUpdated Aug 19, 2026Float Shares
94.48MSharesUpdated Aug 19, 2026% Held by Insiders
57.71%vs all stocks
% Held by Institutions
10.89%vs all stocks
Total Cash (MRQ)
2.67BCNY396.05M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.03CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.02BCNY151.42M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2142xvs Medical Devices peers
Current Ratio (MRQ)
2.07xvs Medical Devices peers
Book Value per Share (MRQ)
23.08CNYUpdated Aug 19, 2026Total Assets
6.63BCNY983.07M · vs all stocks (USD)
Total Current Assets
3.84BCNYFY2025 · Dec 31, 2025Total Liabilities
1.73BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.79BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
137.26MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.59BCNYFY2025 · Dec 31, 2025Cash
1.34BCNYFY2025 · Dec 31, 2025Cash Equivalents
84.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.42BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
404.79MCNYFY2025 · Dec 31, 2025Inventory
675.50MCNYFY2025 · Dec 31, 2025Accounts Payable
639.05MCNYFY2025 · Dec 31, 2025Short-term Debt
758.14MCNYFY2025 · Dec 31, 2025Other Current Liabilities
13.77MCNYFY2025 · Dec 31, 2025Long-term Debt
68.04MCNYFY2025 · Dec 31, 2025Common Stock (Book)
208.90MCNYFY2025 · Dec 31, 2025Retained Earnings
769.75MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.90BCNY727.10M · vs all stocks (USD)
Treasury Stock
140.47MCNYFY2025 · Dec 31, 202552-Week Low
37.70CNYUpdated Aug 19, 202652-Week High
63.99CNYUpdated Aug 19, 202652-Week Change
15.64%vs all stocks
Beta
0.6170xvs all stocks
50-Day MA
49.19CNYUpdated Aug 19, 2026200-Day MA
50.95CNYUpdated Aug 19, 2026Avg 10-Day Volume
1.88MSharesUpdated Aug 19, 2026Avg 30-Day Volume
2.48MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.88CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.28: safe zoneNotable
Altman Z-Score: 5.28
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.7B, above the global median of $1.15BNotable
Market cap (USD): 1,699,149,814.107Global Median: 1,146,734,693.424
Revenue is $543.09M, above the global median of $520.53MNotable
Revenue (USD): 543,085,742.669Global Median: 520,528,949.311
Levered free cash flow is $88.26M, above the global median of $16.24MNotable
Levered free cash flow (USD): 88,263,395.418Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Safety Shot Inc.
Tier 1ProductionApproval-Gated PipelineFlowAttention
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities